REXN
Rexahn Pharmaceuticals, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Market Cap: 8.38 Million
Primary Exchange: NASDAQ
Website: http://www.rexahn.com
Shares Outstanding: 4.48 Million
Float: 4.47 Million
Dividend: (%)
Beta: -0.0003715709826317399
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 340 trading days
From: 2019-07-09 To: 2020-11-04
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|